Zilebesiran: A Novel RNA Interference Therapeutic for Hypertension.

Hypertension remains a leading modifiable risk factor for cardiovascular morbidity and mortality, yet blood pressure control rates are suboptimal, partly due to adherence challenges with daily medications. Zilebesiran is an investigational small interfering RNA therapy targeting hepatic angiotensinogen synthesis to achieve prolonged suppression of the renin-angiotensin-aldosterone system. By conjugating the small interfering RNA to N-acetylgalactosamine, zilebesiran is delivered specifically to hepatocytes, leading to >90% reductions in circulating angiotensinogen and consequently lower angiotensin II levels.

Mid and long-term follow-up of 50 pediatric cardiac Chadians operated in France from 2003 to 2012.

Introduction: cardiac valvular diseases (CVDs) are the major cause of cardiovascular morbidity and mortality globally, with predominance of rheumatic heart disease (RHD) in developing countries. Congenital heart defects (CHD) diagnoses are delayed due to socioeconomic factors. This study aims to evaluate the post-operative surgical outcomes of CHD and valvular RHD.

Statin-induced necrotizing autoimmune myopathy: a systematic review.

Statins are a class of lipid-lowering medications used worldwide by millions of people and are safe for frequent use in most patients. However, they cause necrotizing autoimmune myopathy in some patients. We reviewed case reports of 80 patients from 2010 to present diagnosed with statin-induced necrotizing autoimmune myopathy (SINAM), aiming to analyze the clinical, physiological, serologic characteristics and outcomes of SINAM.

Rationalization of the Laboratory Diagnosis for Good Management of Malaria: Lessons from Transitional Methods.

Introduction: Malaria is an endemic disease in sub-Saharan Africa. In clinical practice, the main concern is the overdiagnosis of malaria leading to inappropriate drug prescription without laboratory confirmation.

Objective: This study aimed to evaluate clinical examination reliability compared with translational laboratory methods of malaria diagnosis.

The Safety and Efficacy of Anakinra, an Interleukin-1 Antagonist in Severe Cases of COVID-19: A Systematic Review and Meta-Analysis.

This study aims to assess anakinra's safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous electronic databases were searched and finally 15 studies with a total of 3,530 patients, 757 in the anakinra arm, 1,685 in the control arm were included. The pooled adjusted odds ratio (OR) for mortality in the treatment arm was 0.